Janssen Signs an Option and License Agreement with Mestag to Discover Novel Fibroblast Targets for Inflammatory Disease
Shots:
- Mestag to receive option fees- milestones- royalties and will deploy its specialist fibroblast sub-population biology platform and state-of-the-art data analytics to identify novel therapeutic targets
- Janssen to get an option to exclusive license to develop and commercialize therapies directed against up to two targets emerges from the collaboration
- Apart from this collaboration- Mestag will continue to develop its inflammatory disease and cancer programs as it progresses its pipeline of first-in-class therapeutics towards the clinic
Ref: Mestag Therapeutics | Image: Janssen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com